Close Menu

SAN ANTONIO – The investigational HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) resulted in durable objective responses in a majority of patients with HER2-positive breast cancer who were heavily pretreated, including with T-DM1 (Genentech's Kadcyla) and other existing HER2-targeted treatments, new results from a Phase II clinical trial, DESTINY-Breast01, have shown.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jan
28

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.